| CAS NO: | 55779-48-1 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| Molecular Weight (MW) | 423.46 |
|---|---|
| Formula | C26H21N3O3 |
| CAS No. | 55779-48-1 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 84 mg/mL (198.4 mM) |
| Water: <1 mg/mL | |
| Ethanol: <1 mg/mL | |
| SMILES | C1=CC=C(C=C1)CC2=C3N=C(C(=O)N3C=C(N2)C4=CC=C(C=C4)O)CC5=CC=C(C=C5)O |
| Synonyms | Oplophorus, luciferin; Coelenterazine; CLZN |
| In Vitro | In vitro activity: When monitoring various biological processes, coelenterazine (CTZ) can be catalyzed by luciferases, such as the sea pansy Renilla reniformis (Rluc) and the marine copepod Gaussia princeps (Gluc), which results in emission of blue light. In Gli36-Gluc- or Gli36-Rluc-expressing Gli36 cells, coelenterazine shows a bioluminescence signal. In RIN-5F, 4T1, HCT 116, HEK 293, 293FT, HeLa and INS-1 cells, coelenterazine can be used to assay superoxide anion concentrations Cell Assay: Coelenterazine showed antioxidative properties in primary cultures of rat hepatocytes subjected to the oxidant tert-butyl hydroperoxide (t-BHP). Coelenterazine (3-10 μM) concentration-dependently increased survival and decreased lipid peroxidation in rat hepatocytes treated for 6 hr with t-BHP (250 μM) [2]. In addition, Coelenterazine (10 μmol/l) can be used to assay superoxide anion concentrations in cancer cell lines. |
|---|---|
| In Vivo | the small molecule coelenterazine (5 mg/kg, intravenous administration) was a potential reporter of cancer-associated superoxide anion in the 4T1 breast adenocarcinoma mouse model [1]. Gli36-Rluc or Gli36-Gluc cells were injected into the leg muscle of nude mice. The mice were injected with 4 mg/kg of coelenterazine and imaged by a cooled charge-coupled device camera. |
| Animal model | 5 mg/kg, intravenous administration |
| Formulation & Dosage | Coelenterazine (4 μg/g) formulated from an ethanol stock diluted in sodium phosphate buffer (50 mM). |
| References | Mol Ther. 2012 Apr;20(4):692-3. doi: 10.1038/mt.2012.38; Mol Imaging Biol. 2016 Apr;18(2):166-71. |
m.cnreagent.com